Highlights Poolbeg Pharma PLC

Stocks

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 19:26:34 11/06/2026 +04			5-day change	1st Jan Change
7.688 ^GBX	+0.50%		-9.52%	+90.00%

01:25pm	Poolbeg Pharma Activates First Site for Clinical Trial of Lead Asset	MT
11:21am	Poolbeg Pharma Announces Successful Site Activation For POLB 001 TOPICAL Clinical Trial	CI

Highlights

11:21am	Poolbeg Pharma Announces Successful Site Activation For POLB 001 TOPICAL Clinical Trial	CI
11:05am	Poolbeg Pharma Presents Preclinical Data Posters On POLB 001 At European Hematology Association Congress	CI
05-26	Poolbeg Pharma Reports Positive Meeting With US FDA for Cytokine Release Syndrome Therapy	MT
05-11	Poolbeg Pharma Receives Patent Grant For POLB 001 Cancer Immunotherapy-Induced CRS In Canada	CI
04-28	Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Poolbeg Pharma plc Receives Clinical Trial Authorisation for Polb 001 Topical Trial	CI
03-31	Poolbeg Pharma celebrates Australian patent "milestone"	AN
03-31	Poolbeg Pharma Bags Australian Patent for Cytokine Release Syndrome Drug Candidate	MT
03-31	Poolbeg Pharma plc Receives Grant of First Cancer Immunotherapy-Induced Crs Patent from Ip Australia	CI
12-08	Poolbeg Pharma plc Announces the POLB 001 Trial Is to Feature in Cancer Immunotherapy-Induced CRSResearch Programme	CI
11-20	Poolbeg Pharma Secures European Patent for Severe Influenza Drug Candidate	MT
11-20	Poolbeg Pharma plc Receives European Immunomodulator II Patent Application Covering POLB 001 for the Treatment of Severe Influenza	CI
29/09/25	Poolbeg Pharma PLC Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/09/25	Poolbeg Pharma plc Signs an Agreement for A Specialist Blood Cancer Trials Organization, Accelerating Clinical Trials Limited to Conduct the Upcoming POLB 001 Phase 2A Trial and Secures the Supply of an Approved Bispecific Antibody Drug for the Trial At No Cost to the Company	CI
27/05/25	Poolbeg Pharma's POLB 001 Wins Orphan Drug Designation in US	MT
20/05/25	Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2024	CI
20/05/25	Poolbeg Pharma loss widens; launches GBP4 million equity raise	AN
20/05/25	Earnings Flash (POLB.L) Poolbeg Pharma Reports FY24 Loss GBX-1.16	MT
20/03/25	Poolbeg Pharma plc Receives Korean Intellectual Property Office Grant in Korea	CI
21/02/25	Poolbeg Pharma Says Hookipa Ended Takeover Talks	MT
21/02/25	Poolbeg Pharma shares plummet as Hookipa walks away from possible bid	AN
21/02/25	Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger	RE
20/02/25	Hookipa Pharma rules out making offer for Poolbeg Pharma	AN
20/02/25	Poolbeg Pharma PLC cancelled the acquisition of HOOKIPA Pharma Inc. in a reverse merger transaction.	CI
30/01/25	Poolbeg Pharma Extends Deadline for Hookipa Pharma Takeover Talks	MT